Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
3.74 (1y: +102%)
Market Cap 71.3 M P/E(ttm)
Enterprise Value 65.2 M P/B 6.00
EDAP- NAS (USA)
Edap TMS SA
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$3.74
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash to Debt 0.5
EDAP's Cash to Debt is ranked higher than
62% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3750.67 vs. EDAP: 0.5 )
EDAP' s 10-Year Cash to Debt Range
Min: 0.37   Max: 12.46
Current: 0.5
0.37
12.46
Equity to Asset 0.191
EDAP's Equity to Asset is ranked lower than
68% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.53 vs. EDAP: 0.191 )
EDAP' s 10-Year Equity to Asset Range
Min: 0.18   Max: 0.69
Current: 0.19
0.18
0.69
Z-Score: 1.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry		 vs
history
Operating margin (%) -11.20
EDAP's Operating margin (%) is ranked lower than
65% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 5.80 vs. EDAP: -11.20 )
EDAP' s 10-Year Operating margin (%) Range
Min: -44   Max: -3.7
Current: -11.2
-44
-3.7
Net-margin (%) -4.2
EDAP's Net-margin (%) is ranked lower than
67% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.25 vs. EDAP: -4.2 )
EDAP' s 10-Year Net-margin (%) Range
Min: -53.6   Max: 43
Current: -4.2
-53.6
43
ROE (%) -10.8
EDAP's ROE (%) is ranked lower than
72% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 4.80 vs. EDAP: -10.8 )
EDAP' s 10-Year ROE (%) Range
Min: -142.9   Max: 33.8
Current: -10.8
-142.9
33.8
ROA (%) -2.9
EDAP's ROA (%) is ranked lower than
69% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. EDAP: -2.9 )
EDAP' s 10-Year ROA (%) Range
Min: -35.4   Max: 23.3
Current: -2.9
-35.4
23.3
ROC (Joel Greenblatt) (%) -20.60
EDAP's ROC (Joel Greenblatt) (%) is ranked lower than
69% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 14.00 vs. EDAP: -20.60 )
EDAP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -637.1   Max: -13.5
Current: -20.6
-637.1
-13.5
Revenue Growth (%) -8.6
EDAP's Revenue Growth (%) is ranked higher than
55% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. EDAP: -8.6 )
EDAP' s 10-Year Revenue Growth (%) Range
Min: -8.6   Max: 2.7
Current: -8.6
-8.6
2.7
EBITDA Growth (%) -28.8
EDAP's EBITDA Growth (%) is ranked higher than
64% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: -1.10 vs. EDAP: -28.8 )
EDAP' s 10-Year EBITDA Growth (%) Range
Min: -57.3   Max: 110.1
Current: -28.8
-57.3
110.1
» EDAP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

EDAP Guru Trades in Q2 2012

Robert Bruce 1,565,494 sh (+96.88%)
» More
Q3 2012

EDAP Guru Trades in Q3 2012

Robert Bruce 1,565,494 sh (unchged)
» More
Q4 2012

EDAP Guru Trades in Q4 2012

Robert Bruce 1,565,494 sh (unchged)
» More
Q1 2013

EDAP Guru Trades in Q1 2013

Robert Bruce 1,565,494 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with EDAP



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 6.00
EDAP's P/B is ranked lower than
77% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. EDAP: 6.00 )
EDAP' s 10-Year P/B Range
Min: 0.18   Max: 9.66
Current: 6
0.18
9.66
P/S 2.00
EDAP's P/S is ranked higher than
51% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. EDAP: 2.00 )
EDAP' s 10-Year P/S Range
Min: 0.2   Max: 5.64
Current: 2
0.2
5.64
PFCF 26.60
EDAP's PFCF is ranked higher than
52% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 18.60 vs. EDAP: 26.60 )
EDAP' s 10-Year PFCF Range
Min: 12.62   Max: 62.5
Current: 26.6
12.62
62.5
EV-to-EBIT 1
EDAP's EV-to-EBIT is ranked higher than
98% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 16.25 vs. EDAP: 1 )
EDAP' s 10-Year EV-to-EBIT Range
Min: 32.1   Max: 109.3
Current: 1
32.1
109.3

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 4.4
EDAP's Price/Net Current Asset Value is ranked lower than
85% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 8.90 vs. EDAP: 4.4 )
EDAP' s 10-Year Price/Net Current Asset Value Range
Min: 0.5   Max: 4.8
Current: 4.4
0.5
4.8
Price/Tangible Book 8.8
EDAP's Price/Tangible Book is ranked higher than
59% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. EDAP: 8.8 )
EDAP' s 10-Year Price/Tangible Book Range
Min: 0.2   Max: 9
Current: 8.8
0.2
9
Price/Median PS Value 2.5
EDAP's Price/Median PS Value is ranked higher than
80% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. EDAP: 2.5 )
EDAP' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 2.4
Current: 2.5
0.2
2.4
Earnings Yield (Greenblatt) 97.40
EDAP's Earnings Yield (Greenblatt) is ranked higher than
98% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 5.95 vs. EDAP: 97.40 )
EDAP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 3.1
Current: 97.4
0.9
3.1
Forward Rate of Return (Yacktman) -7.44
EDAP's Forward Rate of Return (Yacktman) is ranked higher than
56% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.03 vs. EDAP: -7.44 )
EDAP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -14.4   Max: -8.7
Current: -7.44
-14.4
-8.7

Business Description

EDAP TMS S.A. was incorporated on December 3, 1979 as a Societe Anonyme organized under the laws of the Republic of France for 60 years from the date of incorporation. It is a holding Company and is responsible for providing common services to its subsidiaries, including preparation and consolidation of the financial statements for the group, complying with the requirements of various regulatory agencies and maintaining the listing of its publicly held securities. Its activity is organized in two divisions: HIFU and UDS (including lithotripsy activities). Through these two divisions, the Company develops, produces and markets minimally invasive medical devices, mainly for urological diseases. It believes that the creation of these two divisions has allowed expanding its market share by optimizing worldwide distribution capabilities, all of which is coordinated through its subsidiaries. It's HIFU and UDS divisions operate in Europe, the Americas, Asia and the rest of the world. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. The HIFU division had total revenues of approximately €9.6 million during the fiscal year ended December 31, 2009. Its HIFU business is quite seasonal and generally linked to lengthy hospital decision and investment processes. In addition to developing, manufacturing and marketing HIFU devices, the HIFU division also generates revenues from leasing equipment, as well as from the sale of disposables, spare parts and maintenance services. Currently, the only commercial product of the Company utilizing HIFU technology is the Ablatherm, an ultrasound guided HIFU device for the treatment of organ-confined prostate cancer. As of December 31, 2009, the HIFU division's patent portfolio contained 49 patents consisting of 19 in the United States, 22 in the European Union and Japan and eight in Israel and the rest of the world. They belong to 25 groups of patents covering key technologies related to therapeutic ultrasound principles, systems and associated software. As of December 31, 2009, its clinical Ablatherm-HIFU result has been published in 35 peer-reviewed renowned journals. The UDS division's main business is producing and marketing devices, known as lithotripters, for the treatment of urinary tract stones by means of ESWL technology. In addition to its manufacturing and selling of lithotripters, the UDS division also generates revenues from the leasing of lithotripters, as well as from the sale of disposables, spare parts and maintenance services. The UDS division offers the Sonolith Praktis to small and mid-size hospitals, while the Sonolith I-Sys and the Sonolith Vision are offered to large hospitals that can afford a fully dedicated and integrated lithotripter. Ablatherm-HIFU device competes with all current treatments for localized tumors, which include
Company Website
Industry: Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ
Traded in other countries:EDA.Germany

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial